JPH0345272A - Ion phoresis device - Google Patents
Ion phoresis deviceInfo
- Publication number
- JPH0345272A JPH0345272A JP17983289A JP17983289A JPH0345272A JP H0345272 A JPH0345272 A JP H0345272A JP 17983289 A JP17983289 A JP 17983289A JP 17983289 A JP17983289 A JP 17983289A JP H0345272 A JPH0345272 A JP H0345272A
- Authority
- JP
- Japan
- Prior art keywords
- voltage
- electrodes
- introducing
- introducing electrodes
- electric current
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000012466 permeate Substances 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims description 19
- 230000005540 biological transmission Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 5
- 230000005684 electric field Effects 0.000 description 4
- 230000028161 membrane depolarization Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000004020 conductor Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000615 nonconductor Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000010356 wave oscillation Effects 0.000 description 1
Landscapes
- Electrotherapy Devices (AREA)
Abstract
Description
【発明の詳細な説明】
「産業上の利用分野]
本発明は、医療分野で鋭意研究が行なわれている[)
[) 3 (drug delivery syste
m)の−手段として、イオントフオレーシスの原理を用
いた経皮的薬剤投与に使用するイオントフォレーシス用
デバイスに関する。[Detailed Description of the Invention] “Industrial Application Field” The present invention is being intensively researched in the medical field [)
[) 3 (drug delivery system
As a means of m), the present invention relates to an iontophoresis device used for transdermal drug administration using the principle of iontophoresis.
[従来技術とその問題点]
イオントフォレーシスは公知の通り、微弱な直流電流に
より薬剤を経皮的且つ無痛的に投与する方法であり、有
効成分の薬剤を体外から皮下へ浸透させる基本的な駆動
力は電界即ちクーロン力である。[Prior art and its problems] As is well known, iontophoresis is a method of percutaneously and painlessly administering drugs using a weak direct current. The driving force is an electric field, or Coulomb force.
ところで、皮膚の最外層を構成する角質は、電気的に絶
縁体の性質を持つため直流電界をかけると絶縁体は誘導
分極を起こす。そこで、公知の通り、皮膚の電気等価回
路はキャパシタンス(C)とレジスタンス(R)との並
列結合回路で表現される。By the way, the stratum corneum that constitutes the outermost layer of the skin has the property of being an electrical insulator, so when a DC electric field is applied, the insulator undergoes induced polarization. Therefore, as is well known, the electrical equivalent circuit of the skin is expressed by a parallel combination circuit of capacitance (C) and resistance (R).
従って皮膚に直流電界をか←プるとキャパシタンスに対
する充電電流が過渡的に流れるが、レジスタンスの抵抗
値がかなり大きな値を持つため定常的にはほとんど電流
が流れない状態になる。Therefore, when a DC electric field is applied to the skin, a charging current flows transiently to the capacitance, but since the resistance value of the resistor is quite large, almost no current flows steadily.
このため直流電界によるイオントフオレーシスは、駆動
力である電流が流れないため、薬剤の浸透の効率が極め
て悪くなる問題がある。この問題を解消する方法として
特開昭60i56475号公報。For this reason, iontophoresis using a DC electric field has a problem in that the efficiency of drug penetration is extremely poor because no current, which is the driving force, flows. Japanese Patent Laid-Open No. 60i56475 discloses a method for solving this problem.
特開昭60−188176号公報、特開昭61−.31
169号公報等には、電極間に治療パルスを出力し、パ
ルス休止期間中に関導子と不関導子の両電極間を短絡す
るスイッチ機構や該両電極間に逆極性のパルスを印加す
る機構を設(Jて脱分極させる方法が開示されている。JP-A-60-188176, JP-A-61-. 31
Publication No. 169, etc. describes a switch mechanism that outputs a therapeutic pulse between the electrodes and short-circuits the two electrodes, a seki conductor and an insensible conductor, during the pulse pause period, and a switch mechanism that applies a pulse of opposite polarity between the two electrodes. A method is disclosed in which a mechanism for depolarization is provided.
しかしながらこの方法では脱分極の機構と、休止期間中
に該機構を動作させるための同期機構が必要となるため
装置が大型化してしまう問題がある。However, this method requires a depolarization mechanism and a synchronization mechanism for operating the mechanism during the rest period, resulting in an increase in the size of the device.
方、糖尿病患者へのインスリン投与等実際の使用におい
ては、デバイスを携行容易な腕時計や腕章サイズに小型
化して、患者の日常生活や就労の不便を無くすことが望
まれている。On the other hand, in actual use such as administering insulin to diabetic patients, it is desired that the device be miniaturized to the size of a wristwatch or armband for easy carrying, thereby eliminating the inconvenience in patients' daily life and work.
[発明の目的]
本発明は、かかる問題を解消すべく研究の結果なされも
ので、小型で、しかも、イオントフォレーシスに必要な
電流を効率良く流すことのできるイオントフォレーシス
用デバイスを目的としたものである。[Purpose of the Invention] The present invention was made as a result of research to solve such problems, and its purpose is to provide a device for iontophoresis that is small and can efficiently flow the current necessary for iontophoresis. That is.
[発明の構成9作用」 前述の目的は、以下の本発明により達成される。[Construction 9 of the invention] The above objects are achieved by the invention as follows.
すなわち本発明は、少なくとも一方が薬剤を含有した電
極間に電圧を印加し、薬剤を浸透させるようにしたイオ
ンフAレーシス用デバイスにおいて、前記電圧を所定周
波数の交流電圧としたことを特徴とづるイオントフォレ
ーシス用デバイスである。That is, the present invention provides an ion pharesis device in which a voltage is applied between electrodes, at least one of which contains a drug, to cause the drug to penetrate, wherein the voltage is an alternating current voltage with a predetermined frequency. It is a device for tophoresis.
上記の通り、本発明は従来の直流電圧あるいは方向パル
スと異なり、両方向の交流電圧を印加するので、皮膚の
分極電荷は反転する半サイクルで自動的に放電され、薬
剤浸透に必要な電流を充分に流すことができる。なお交
流電圧により薬剤が浸透するのは浸透現象の不可逆性に
よるものと考えられる。As mentioned above, unlike conventional DC voltage or directional pulses, the present invention applies AC voltage in both directions, so that the polarized charge on the skin is automatically discharged in a half cycle of reversal, and the current required for drug penetration is sufficient. can be passed to. It is thought that the reason why the drug permeates due to alternating current voltage is due to the irreversibility of the permeation phenomenon.
このように本発明では、分極電荷は自動的に放電される
ので、従来例の如く特別な脱分極手段が不要となり、小
型で安価なデバイスが実現される。As described above, in the present invention, since the polarized charges are automatically discharged, there is no need for special depolarization means as in the conventional example, and a small and inexpensive device can be realized.
3−
特に、両電極を薬剤を含有せしめた導入電極とすること
により、薬剤は両電極から浸透されるので、必要な電極
面積が従来の一方の電極からのみ投入する場合に比較し
て大巾に小さくでき、それだけ小型化できる。3- In particular, by using both electrodes as introduction electrodes containing a drug, the drug is infiltrated from both electrodes, so the required electrode area is larger compared to the conventional case of injecting only from one electrode. It can be made smaller, and the size can be made that much smaller.
また、交流電圧の周波数は、イオントフォレーシスに必
要と言われる数′m、八以への電極を乾電池等の小型電
源から供給できるという点からioo。In addition, the frequency of the alternating current voltage is several meters, which is said to be necessary for iontophoresis, and the electrodes can be supplied from a small power source such as a dry battery.
口2以上が好ましく、更に皮膚のインピーダンスが1に
Ω以下となる5000トlz以上の高周波が好ましい。A frequency of 2 or more is preferable, and a high frequency of 5,000 torr or more at which the impedance of the skin is 1 to Ω or less is more preferable.
なおその波形については正弦波、矩形波。The waveforms are sine waves and square waves.
−角波等すべて適用でき、特に限定されない。- All angle waves etc. can be applied and are not particularly limited.
以下、本発明を実施例に基いて説明する。The present invention will be explained below based on examples.
第1図は実施例の全体を示す側面図、第2図はその底面
図、第3図はその電気回路構成を示すブロック図である
。FIG. 1 is a side view showing the entire embodiment, FIG. 2 is a bottom view thereof, and FIG. 3 is a block diagram showing the electric circuit configuration thereof.
本例は携行使用に便利な一体型の例であり、長方形の可
撓性のある絶縁体の支持板1の長手方向の両側に導入電
極2.3を所定間隔隔てて配置し、その中央部に電気回
路部4を配した構成となって一
4−
いる。導入電極2,3は金、アルミニウム等の金属電極
21.31上にイオン性薬剤を含有せしめたフィルム状
の導電性ゲル層22.32を積層した公知の構成である
。なおかかる導入電極2,3には前述の特開昭60−1
56475号公報等に開示のもの、その他市販のもの等
公知のものが適用できるので、その詳細説明は省略する
。又本例では小型用に両電極を共に薬剤を含有させた導
入電極としているが、方は薬剤を含有しない単なる導電
性電極としてもJ:い。This example is an integrated type example that is convenient for carrying.Introducing electrodes 2.3 are arranged at a predetermined interval on both sides of the support plate 1 made of a rectangular flexible insulator in the longitudinal direction. It has a configuration in which an electric circuit section 4 is arranged at the top. The introduction electrodes 2 and 3 have a known structure in which a film-like conductive gel layer 22.32 containing an ionic drug is laminated on a metal electrode 21.31 made of gold, aluminum, or the like. The introduction electrodes 2 and 3 are as described in the above-mentioned Japanese Patent Application Laid-open No. 60-1.
Since known methods such as those disclosed in Japanese Patent No. 56475 and other commercially available products can be applied, detailed explanation thereof will be omitted. Further, in this example, both electrodes are used as introducing electrodes containing a drug for small size, but the other electrode may be used as a mere conductive electrode that does not contain a drug.
そして、電気回路部4は導入電極2,3に所定周波数の
交流電圧を供給するように第3図のように構成されてい
る。すなわち、図にJ3いて、41は時計用電池等の小
型電池からなる電源、42は電源オンオフ用のスイッチ
、43は正弦波発信回路、44は安全のための電流制限
用抵抗である。図の5は人体の腕等の所定部位である。The electric circuit section 4 is constructed as shown in FIG. 3 so as to supply an alternating current voltage of a predetermined frequency to the introduction electrodes 2 and 3. That is, in the figure, J3 indicates a power source 41 consisting of a small battery such as a watch battery, 42 a power on/off switch, 43 a sine wave oscillation circuit, and 44 a current limiting resistor for safety. 5 in the figure is a predetermined part of the human body, such as an arm.
上述の構成において、導入電極2,3が人体の所定部位
の皮膚に密着するようにセットしてスイッチ42をオン
にすると正弦波発信回路43が動作し G−
て導入電極2.3には正弦波交流電圧が印加される。づ
るど、該電圧に応じた電流が導入電極2゜3間に流れ、
該電流に応じて導入電極2,3の導電性ゲル層22.2
3に含有性しめた薬剤が皮膚下へ浸透する。従って治療
目的に適した薬剤を選定することにより種々の治療に利
用することができる。In the above configuration, when the introduction electrodes 2 and 3 are set so as to be in close contact with the skin of a predetermined part of the human body and the switch 42 is turned on, the sine wave transmitting circuit 43 is operated. A wave alternating current voltage is applied. A current corresponding to the voltage flows between the introducing electrodes 2 and 3,
The conductive gel layer 22.2 of the introduction electrodes 2, 3 depending on the current
The drug contained in step 3 penetrates under the skin. Therefore, by selecting a drug suitable for the therapeutic purpose, it can be used for various treatments.
ところで、イオントフォレーシスでは薬剤の浸透は流れ
る電流と強い相関を右づることが知られており、確認テ
ス1〜として上記実施例を人体の腕部に取り伺け、薬剤
は使用吐す、周波数を変えてその流れる電流を測定した
。その結果、波高値3Vという低電圧で、周波数100
0Hzで約1mA。By the way, in iontophoresis, it is known that the penetration of the drug has a strong correlation with the flowing current, and as confirmation test 1~, take the above example to the arm of a human body, use the drug, and vomit. The flowing current was measured by changing the frequency. As a result, the voltage is as low as 3V, and the frequency is 100.
Approximately 1mA at 0Hz.
周波数5 K l−I Zで約4.mA、10KHzで
約6mA。Approximately 4.0 at frequency 5Kl-IZ. mA, approximately 6mA at 10KHz.
100に+−12で約13mAであった。なお、この時
電流制限抵抗は100Ωとした。It was about 13 mA at +-12 to 100. Note that the current limiting resistance at this time was 100Ω.
これより10001−12以上の高周波交流電圧を印加
することにより、小型電池を電源とした携帯して使用で
きる小型イオントフォレーシス用デバイスの実現できる
ことが確認された。From this, it was confirmed that by applying a high-frequency AC voltage of 10001-12 or more, it was possible to realize a small-sized iontophoresis device that was powered by a small battery and was portable.
以上本発明を実施例に基いて説明したが、デバイスの形
状、電気回路の構成等本発明はかかる実施例に限定され
ないことば、本発明の趣旨から明らかである。Although the present invention has been described above based on Examples, it is clear from the gist of the present invention that the present invention is not limited to such Examples, such as the shape of the device and the structure of the electric circuit.
以上の通り、本発明は、従来の一方向電圧と異なる両方
向の交流電圧により薬剤を浸透させることを特徴とする
ものであり、イオントフォレーシス用デバイスの小型化
、更にはイオントフォレーシスの適用範囲の拡大に大き
な寄与をなすものである。As described above, the present invention is characterized by infiltrating a drug using a bidirectional alternating current voltage, which is different from the conventional one-way voltage. This will greatly contribute to expanding the scope of application.
第1図は実施例の全体側面図、第2図はその底面図、第
3図はその電気回路部のブロック図である。。
1:支持板、 2,3:導入電極。
4:電気回路部。FIG. 1 is an overall side view of the embodiment, FIG. 2 is a bottom view thereof, and FIG. 3 is a block diagram of the electric circuit section thereof. . 1: Support plate, 2, 3: Introducing electrode. 4: Electric circuit section.
Claims (1)
加し、薬剤を浸透させるようにしたイオントフォレーシ
ス用デバイスにおいて、前記電圧が所定周波数の交流電
圧であることを特徴とするイオントフォレーシス用デバ
イス。 2、前記交流電圧が1000Hz以上の高周波交流電圧
である請求項第1項記載のイオントフォレーシス用デバ
イス。 3、両電極が薬剤を含有した導入電極である請求項第1
項又は第2項記載のイオントフォレーシス用デバイス。[Claims] 1. In an iontophoresis device in which a voltage is applied between electrodes, at least one of which contains a drug, to cause the drug to permeate, the voltage is an alternating current voltage with a predetermined frequency. Features of iontophoresis device. 2. The iontophoresis device according to claim 1, wherein the AC voltage is a high frequency AC voltage of 1000 Hz or more. 3. Claim 1, wherein both electrodes are introduction electrodes containing a drug.
The iontophoresis device according to item 1 or 2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17983289A JPH0345272A (en) | 1989-07-12 | 1989-07-12 | Ion phoresis device |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17983289A JPH0345272A (en) | 1989-07-12 | 1989-07-12 | Ion phoresis device |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0345272A true JPH0345272A (en) | 1991-02-26 |
Family
ID=16072677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP17983289A Pending JPH0345272A (en) | 1989-07-12 | 1989-07-12 | Ion phoresis device |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0345272A (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0549702A (en) * | 1991-08-28 | 1993-03-02 | Teijin Ltd | Iontophoresis device |
WO1994028967A1 (en) * | 1993-06-08 | 1994-12-22 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoresis system |
US7137975B2 (en) | 2001-02-13 | 2006-11-21 | Aciont, Inc. | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent |
JP2012517321A (en) * | 2009-02-12 | 2012-08-02 | インキューブ ラブス エルエルシー | Iontophoresis system for transdermal delivery of active agents for therapeutic and pharmaceutical purposes |
US8903485B2 (en) | 2009-08-06 | 2014-12-02 | Incube Labs, Llc | Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes |
US8961492B2 (en) | 2009-02-12 | 2015-02-24 | Incube Labs, Llc | System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation |
US9008765B2 (en) | 2009-02-12 | 2015-04-14 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings |
US9095503B2 (en) | 2009-02-12 | 2015-08-04 | Incube Labs, Llc | System and method for biphasic transdermal iontophreotic delivery of therapeutic agents |
US10035015B2 (en) | 2010-02-10 | 2018-07-31 | Incube Labs, Llc | Methods and architecture for power optimization of iontophoretic transdermal drug delivery |
US10076651B2 (en) | 2009-12-07 | 2018-09-18 | Incube Labs, Llc | Iontophoretic apparatus and method for marking of the skin |
-
1989
- 1989-07-12 JP JP17983289A patent/JPH0345272A/en active Pending
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0549702A (en) * | 1991-08-28 | 1993-03-02 | Teijin Ltd | Iontophoresis device |
WO1994028967A1 (en) * | 1993-06-08 | 1994-12-22 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoresis system |
US5695459A (en) * | 1993-06-08 | 1997-12-09 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoresis system |
US7137975B2 (en) | 2001-02-13 | 2006-11-21 | Aciont, Inc. | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent |
US9849281B2 (en) | 2009-02-12 | 2017-12-26 | Incube Labs, Llc | System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation |
US9764131B2 (en) | 2009-02-12 | 2017-09-19 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents |
US8961492B2 (en) | 2009-02-12 | 2015-02-24 | Incube Labs, Llc | System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation |
JP2015042303A (en) * | 2009-02-12 | 2015-03-05 | インキューブ ラブス エルエルシーIncube Labs, Llc | Ion introduction system for activator transdermal delivery for medical treatment and pharmaceutical purposes |
US9008765B2 (en) | 2009-02-12 | 2015-04-14 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings |
US9095503B2 (en) | 2009-02-12 | 2015-08-04 | Incube Labs, Llc | System and method for biphasic transdermal iontophreotic delivery of therapeutic agents |
US9533142B2 (en) | 2009-02-12 | 2017-01-03 | Incube Labs, Llc | Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes |
JP2017077487A (en) * | 2009-02-12 | 2017-04-27 | インキューブ ラブス エルエルシーIncube Labs, Llc | Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes |
US10806924B2 (en) | 2009-02-12 | 2020-10-20 | Incube Labs, Llc | Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes |
US10780266B2 (en) | 2009-02-12 | 2020-09-22 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic therapeutic agents |
US9775994B2 (en) | 2009-02-12 | 2017-10-03 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings |
JP2012517321A (en) * | 2009-02-12 | 2012-08-02 | インキューブ ラブス エルエルシー | Iontophoresis system for transdermal delivery of active agents for therapeutic and pharmaceutical purposes |
US10556106B2 (en) | 2009-02-12 | 2020-02-11 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings |
US10245428B2 (en) | 2009-02-12 | 2019-04-02 | Incube Labs, Llc | Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes |
US10695561B2 (en) | 2009-08-06 | 2020-06-30 | Incube Labs, Llc | Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes |
US8903485B2 (en) | 2009-08-06 | 2014-12-02 | Incube Labs, Llc | Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes |
US9750935B2 (en) | 2009-08-06 | 2017-09-05 | Incube Labs, Llc | Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes |
US10076651B2 (en) | 2009-12-07 | 2018-09-18 | Incube Labs, Llc | Iontophoretic apparatus and method for marking of the skin |
US10035015B2 (en) | 2010-02-10 | 2018-07-31 | Incube Labs, Llc | Methods and architecture for power optimization of iontophoretic transdermal drug delivery |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5658247A (en) | Ionosonic drug delivery apparatus | |
US7069073B2 (en) | Electrokinetic delivery of medicaments | |
US6223076B1 (en) | Sweat control system | |
US9186506B2 (en) | Portable unit for treating chronic pain | |
US11717658B2 (en) | Skin care device | |
CA2102759A1 (en) | Electrical stimulation for treatment of osteoarthritis | |
AU2008203298A1 (en) | Device and method for controlled delivery of active substance into the skin | |
JPH0345272A (en) | Ion phoresis device | |
WO1993010854A1 (en) | Iontophoretic delivery device and power supply therefor | |
US8747383B2 (en) | Process and system for iontophoretic wrinkle reduction | |
US20090292328A1 (en) | Medical Device | |
JP2809510B2 (en) | System for iontophoresis | |
JPH0245461B2 (en) | ||
JP4360734B2 (en) | Electronic skin care device | |
JPS627866B2 (en) | ||
JP3003001U (en) | Manual device for ion penetration treatment | |
EP1163025B1 (en) | Sweat control system | |
JP3665632B2 (en) | Iontophoresis device and electronic beauty device | |
JP2889024B2 (en) | Equipment for iontophoresis | |
WO2002072193A1 (en) | Device for iontoforesis | |
JPH0349754A (en) | Ultrasonic treatment aid | |
JPS58124457A (en) | Ion introducing electronic beauty device | |
CN219517546U (en) | Transdermal drug delivery device | |
JPH0345271A (en) | Ion phoresis device | |
JPH02241464A (en) | Device for iontophoresis |